Matsuda 2008 [47] | Hewett 2010 [37] | Leufkens 2011 [38] | Ikematsu 2012 [17] | Gralnek 2014 [36] | Dik 2015 [5] | Halpern 2015 [39] | Min 2017 [26] | Papanikolaou 2017 [40] | Triantafyllou 2017 [41] | De Palma 2018 [42] | Riu Pons 2020 [35] | Wang 2020 [43] | Kamba 2021 [44] | Glissen Brown 2022 [45] | Wallace 2022 [46] | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Country | J | USA | USA, NL, I, B, UK | J | NL, USA, IL | NL, USA, IL | IL, D | China | GR | GR | I | Spain | China | J | USA | I, UK, USA |
Type of NCT | IE-CT | BF-CT | BF-CT | IE-CT | BF-CT | BF-CT | BF-CT | IE-CT | BF-CT | BF-CT | BF-CT | IE-CT | CADe | CADe | CADe | CADe |
Total randomized, n | 167 | 100 | 448 | 813 | 197 | 126 | 126 | 152 | 220 | 200 | 288 | 41 | 382 | 358 | 234 | 249 |
NCT-WLC randomized, n | 83 | 52 | 226 | 406 | 101 | 62 | 66 | 77 | 110 | 100 | 144 | 21 | 192 | 179 | 116 | 116 |
NCT-WLC included, n | 83 | 52 | 176 | 389 | 97 | 57 | 52 | 71 | 107 | 100 | 137 | 21 | 184 | 171 | 113 | 109 |
WLC-NCT randomized, n | 84 | 48 | 222 | 407 | 96 | 64 | 60 | 75 | 110 | 100 | 144 | 20 | 190 | 179 | 116 | 114 |
WLC-NCT included, n | 84 | 48 | 173 | 393 | 88 | 59 | 54 | 70 | 108 | 100 | 137 | 20 | 185 | 173 | 110 | 104 |
Age NCT-WLC | 62 ± 10a | 61 (1)b | 58 (23–79)C | 63 (10)b | 57 (21–70)c | 58 ± 9a | 58 ± 8a | 46 ± 13c | 62 (10)b | 61 (10)b | 55 ± 13a | 60d | 48 ± 10.82a | 61 ± 9.89a | 61 ± 9.83a | 63 ± 8.2a |
Age WLC-NCT | 62 ± 9.5a | 63 (1.2)b | 57 (26–83)c | 63 (9.9)b | 56 (22–70)c | 60 ± 9.3a | 55 ± 7.9a | 48 ± 13.1c | 64 (9.5)b | 61 (9.6)b | 56 ± 12.3a | 59d | 47 ± 10.38a | 61 ± 10.01a | 61 ± 8.45a | 65 ± 8.1a |
Females NCT-WLC, n (%) | 25 (30) | 24 (46) | 54 (31) | 122 (31) | 55 (57) | 16 (28) | 31 (60) | 34 (48) | 61 (56) | 46 (46) | 66 (48) | 8 (39) | 91 (49) | 42 (24) | 59 (52) | 36 (31) |
Females WLC-NCT, n (%) | 35 (42) | 19 (40) | 63 (36) | 116 (30) | 46 (52) | 29 (49) | 29 (54) | 32 (46) | 58 (52) | 48 (48) | 65 (47) | 11 (55) | 99 (54) | 41 (23) | 42 (38) | 37 (32) |
∅ adenoma. NCT- WLC | 0.80 | 2.02 | 0.77 | 1.00 | 0.61 | 1.18 | 0.77 | NR | 0.68 | 1.09 | 0.64 | 1.57 | 0.78 | 1.42 | 1.50 | 2.12 |
∅ adenoma. WLC-NCT | 1.13 | 2.77 | 0.86 | 1.09 | 0.56 | 0.98 | 0.70 | NR | 0.74 | 0.86 | 0.74 | 1.20 | 0.65 | 1.25 | 1.31 | 2.17 |
Colon examined | RC | WC | WC | RC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC | WC |
Setting | NR | A | A, non A | A | A, non A | A, non A | A, non A | A, non A | A, non A | A, non A | A | non A | non A | A, non A | A | A, non A |
Single/multi center | Single | Single | Multi | Multi | Multi | Multi | Multi | Multi | Multi | Multi | Single | Single | Single | Multi | Multi | Multi |
Type tandem study | Type I | Type I | Type I | Type I | Type I | Type I | Type I | Type II | Type I | Type I | Type II | Type I | Type I | Type I | Type I | Type I |
Endoscopists, n | 1 | 2 | 15 | 27 | 15 | 6 | > 1 | > 1 | 5 | 6 | 4 | 5 | 3 | 32 | > 1 | > 1 |
Diff. endoscopist 2nd | No | No | No | No | No | No | No | Yes | No | No | No | No | No | No | No | No |
Endoscopist blinded alloc. | NR | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | NR | Yes | Yes | Yes | Yes | Yes | Yes |